Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | CTSS | P25774 | 9/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14254842 | 0.87 | SCN9A (0.44) | SCN9ARENCTSKCTSSCA1 | |
| SCHEMBL607556 | 0.85 | CYP1A2 (0.46) | SCN9ACTSKCTSSCA1CA2 | |
| SCHEMBL7351243 | 0.85 | CYP1A2 (0.46) | SCN9ACTSKCTSSCA1CA2 | |
| SCHEMBL22186264 | 0.84 | CTSK (0.42) | RENCTSKCTSSCA1CA2 | |
| SCHEMBL17840460 | 0.83 | CTSK (0.48) | SCN9ARENCTSKCTSSCA1 | |
| SCHEMBL15071352 | 0.83 | CTSK (0.44) | SCN9ARENCTSKCTSSCA1 | |
| SCHEMBL11596489 | 0.83 | CTSK (0.48) | SCN9ARENCTSKCTSSCA1 | |
| SCHEMBL168412 | 0.83 | CYP2D6 (0.54) | SCN9ARENCTSKCTSSCA1 | |
| SCHEMBL2130020 | 0.83 | CTSK (0.48) | SCN9ARENCTSKCTSSCA1 | |
| SCHEMBL16162484 | 0.80 | CTSK (0.47) | RENCTSKCTSSCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3618833-B1 | TRIPARTITE ANDROGEN RECEPTOR ELIMINATORS, METHODS AND USES THEREOF | SPG THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20200207753-A1 | Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof | SPG THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207753-A1 | Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof | AR, ESRRA, ESRRB | SCN9A 4802/4885REN 1377/4885CTSK 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.